Official blog
Compliance-aware guides and brand updates for adult consumers.
Page 26 of 35 / 832 articles
Philip Morris says it wants to 'unsmoke the world.' If it succeeds, what kind of company will it become—and can it be trusted to manage the transition it claims to be leading?
The standard answer—'because they're addicted to nicotine'—is true but incomplete. People smoke for reasons that are social, psychological, cultural, and economic. Addressing smoking requires understanding all of them.
Overwhelmed by the nicotine evidence? Here's a curated guide to the most important studies, reviews, and reports—organized by topic, with context on what each contributes and what it leaves open.
The series concludes—not because the topic is exhausted, but because every inquiry must have an ending. A final reflection on nicotine, evidence, policy, and the human capacity for change.
Projecting forward from 2026: the products, the policies, the culture, and the health outcomes of the nicotine world two decades from now. A speculative but evidence-grounded forecast.
To the readers of 2035 and beyond: this is what we knew, what we argued about, and what we hoped for. May you have resolved the debates we couldn't.
Nicotine policy involves trade-offs between competing values: autonomy vs. protection, present vs. future, individual vs. population. An ethical framework for navigating these trade-offs.
From Stockholm to Shenzhen to São Paulo, the nicotine transition is unfolding differently in every corner of the world. A global tour reveals both the diversity of experience and the common challenges.
Over 200 articles, the nicotine landscape has been mapped from every angle. This final reflection is not a conclusion—the story continues—but an attempt to name what the series has been about, at its deepest level.
Rural Americans smoke at higher rates than urban Americans—and have dramatically less access to cessation services. The geography of smoking cessation is a map of health inequity.
The first generation of nicotine vaccines failed in Phase III trials. The next generation—using monoclonal antibodies, nanoparticle carriers, and genetic immunization—is showing renewed promise.
What's changed, what hasn't, and what's next in nicotine policy. A forward-looking assessment written from the vantage point of 2026, projecting toward the end of the decade.
Flavors aren't just about enjoyment. They're about breaking the psychological association between nicotine and tobacco, creating a clean sensory break that helps former smokers stay quit. The psychology of flavor is underappreciated.
From Hon Lik's first e-cigarette to the WHO's warning on nicotine pouches, the nicotine landscape has been transformed in two decades. A chronological tour of the events that shaped the modern nicotine world.
People with PTSD smoke at two to three times the general population rate. For many, nicotine is a form of self-medication for hyperarousal, emotional numbing, and the cognitive symptoms of trauma. Understanding this connection is essential.
Hookah smoking has exploded globally—particularly among youth and young adults who believe it's safer than cigarettes. It's not. The waterpipe epidemic is the most underappreciated dimension of the global tobacco crisis.
The tools exist to eliminate combustible tobacco within a generation. The evidence supports it. The economics favor it. What's missing is the choice to make it happen. The final article in this series argues for choosing now.
NRT hasn't changed much in 40 years—patches, gum, lozenges. But a quiet revolution in nicotine delivery technology is underway, from smart patches to inhaled nicotine to genetically-guided dosing. What's in the pipeline?
If you had to summarize the entire nicotine policy debate in a single sentence, what would it be? Ten experts give their answers—and the range of responses is instructive.
Behind every e-liquid flavor is a flavorist—a professional trained in the chemistry and sensory science of taste. The craft of e-liquid flavor development is sophisticated, largely invisible, and central to the vaping experience.
Governments worldwide collect over $250 billion annually in tobacco taxes. That revenue funds healthcare, education, and children's programs. The fiscal dependency on smoking is the single greatest barrier to ending it.
Smoking accelerates biological aging—not just in the lungs and skin, but at the cellular level. Telomere shortening, epigenetic clocks, and mitochondrial dysfunction all point to nicotine's role in the aging process.
The first 100 articles mapped the nicotine landscape. Another 100 articles later, what's changed? The evidence has advanced. The policy battles have intensified. And the fundamental tensions remain unresolved.
The tobacco control establishment was forged in the battles against Big Tobacco in the 1990s. A new generation of researchers, shaped by harm reduction and digital culture, is challenging the old orthodoxies.
Products
Select a product to view details, highlights, and technical specifications.
